Product Description: TARC/CCL17 Protein, Human (HEK293, His) is the first CC chemokine identified to interact with T cells with high affinity and bind to the CCR4 receptor to mediate inflammation, cancer, and autoimmune related diseases. TARC/CCL17 Protein, Human (HEK293, His) is a recombinant human TARC/CCL17(A24-S94) protein expressed by HEK293 with a his tag at C end[1][2].
Formula: 6361(Gene_ID)Q92583 (A24-S94)(Accession)
References: [1]Stefanie Scheu, et al. The C-C Chemokines CCL17 and CCL22 and Their Receptor CCR4 in CNS Autoimmunity. Int J Mol Sci. 2017 Nov 2;18(11):2306./[2]Kashif Rasheed, et al. CCL17/TARC and CCR4 expression in Merkel cell carcinoma. Oncotarget. 2018 Jul 31;9(59):31432-31447./[3]Julien Catherine, et al. What does elevated TARC/CCL17 expression tell us about eosinophilic disorders? Semin Immunopathol. 2021 Jun;43(3):439-458./[4]Jan Korbecki, et al. CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of the Ligands of Receptors CCR1, CCR2, CCR3, and CCR4. Int J Mol Sci. 2020 Nov 9;21(21):8412./[5]Yoshiki Mizukami, et al. CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer. Int J Cancer. 2008 May 15;122(10):2286-93./[6]Amr A Al-haidari, et al. CCR4 mediates CCL17 (TARC)-induced migration of human colon cancer cells via RhoA/Rho-kinase signaling. Int J Colorectal Dis. 2013 Nov;28(11):1479-87.
Molecular Weight: Approximately 10-13 kDa
Compound Purity: 98.0
English
Deutsch
